This content is provided by an external author without editing by Finextra. It expresses the views and opinions of the author. As the first live implementation of 1st's new Adviser Evolution ...

Sirnaomics Ltd. has completed IND-enabling studies for STP-125G, a single-stranded siRNA therapeutic targeting apolipoprotein C3 (ApoC3), based on its proprietary Galahead mxRNA technology.